Long-term enalapril treatment in diabetic nephropathy.
A randomized comparison of enalapril and metoprolol in patients with type 1 diabetes and nephropathy showed that the decline in kidney function was 5.6 +/- 5.9 ml/min/year in the metoprolol-treated and 2.0 +/- 3.2 ml/min/year in the enalapril-treated patients (P = 0.02). In the present study, the enalapril treated patients have been studied for two additional years. In the metoprolol-treated group, only the endpoints of death or uremia have been recorded, and six of the patients have reached end-stage renal failure and three are dead, compared to three and two, respectively in the enalapril treated group. The mean fall in glomerular filtration rate in 18 enalapril-treated patients is 8.4 +/- 9.4 ml/min/1.73 m2 after four years; 7.5 +/- 9.8 ml/min/1.73 m2, occurred during the first six months treatment. The mean decline in kidney function was 1.7 +/- 2.4 ml/min/year over the whole study period and 0.3 +/- 3.9 ml/min/year after exclusion of the first six months. In this study, long-term enalapril treatment in diabetic nephropathy was associated with a low rate of decline in kidney function.
Mulec
H
H
Department of Nephrology, Sahlgrenska Hospital, University of Göteborg, Sweden.
Johnsen
S A
SA
Björck
S
S
D000328:Adult; D001794:Blood Pressure; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D004656:Enalapril / Q000008:administration & dosage* / Q000627:therapeutic use; D005919:Glomerular Filtration Rate; D006801:Humans; D008790:Metoprolol / Q000627:therapeutic use; D008875:Middle Aged; D011507:Proteinuria / Q000652:urine; D013997:Time Factors
D004656:Enalapril; D008790:Metoprolol